120 results about "Anti hepatitis c virus" patented technology

A nucleoside compound having activity against hepatitis C virus is disclosed.

A purified compound having activity against hepatitis C virus is disclosed.

Recombinant antibodies, including chimeric antibodies, specific for hepatitis C (HCV) antigenic proteins are provided. The recombinant antibodies specifically bind to diagnostically relevant regions of HCV proteins and are thus suitable for use, for example, as diagnostic reagents for the detection of HCV, and / or as standardization reagents or positive control reagents in assays for the detection of HCV. The recombinant antibodies can also be used in the treatment or prevention of a HCV infection.

The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and / or treatment or prevention of HCV infection.

Unsaturated 1-Amino-alkylcyclohexane compounds which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Recombinant antibodies, including chimeric antibodies, specific for hepatitis C (HCV) antigenic proteins are provided. The recombinant antibodies specifically bind to diagnostically relevant regions of HCV proteins and are thus suitable for use, for example, as diagnostic reagents for the detection of HCV, and / or as standardization reagents or positive control reagents in assays for the detection of HCV. The recombinant antibodies can also be used in the treatment or prevention of a HCV infection.

The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

The present invention provides novel methods for preparing a key intermediate, 3,5-di-O-acyl-2-fluoro-2-C-methyl-D-ribono-γ-lactone (2), for the preparation of 1-(2-deoxy-2-fluoro-2-C-methyl-β-D-ribofuranosyl)cytosine (1), which is a potent and selective anti-hepatitis C virus agent.

The invention discloses preparation of a neutralizing monoclonal antibody of an anti-hepatitis C virus and application thereof. E2 protein is utilized to strengthen immunity after mice are immunized by pVAX-CpG-N2N8; spleen of the mice with the highest valence aiming at the E2 antibody is taken as an antigen-sensitized B cell and fused with a myeloma cell SP2 / 0 strain, and the fused cell is screened in HAT culture medium, so as to obtain the fused cell, and the fused grows and is cloned to obtain the hybridoma cell strain generating the monoclonal antibody disclosed by the invention. The neutralizing monoclonal antibody of the anti-hepatitis C virus E2 disclosed by the invention is generated by the hybridoma cell strain; epitope combined with the monoclonal antibody is at F550GCTWMNSTGFTKVCGAPPCVIG572 part of E2 glycoprotein. The neutralizing monoclonal antibody of the anti-hepatitis C virus disclosed by the invention has good capability of neutralizing HCV infection, can be used as a hepatitis C virus therapeutic antibody, and has a great application prospect in hepatitis C diagnosis and treatment.

Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.

The invention relates to a preparation method for sofosbuvir intermediates 9, 11. The preparation method comprises the following steps: by taking a compound I as an initial material, carrying out an additive reaction with electrophilic reagents acrylonitrile, cyanoacetylene, propargyl ester and acrylate and carrying out ring-closing reaction to prepare corresponding intermediates (VII, V, IV and II); carrying out a ring-opening reaction on the intermediates (VII, V, IV and II) and a fluorination reagent to obtain corresponding intermediates (VIII, VI, II and III), carrying out a reaction on the intermediate VIII and benzoyl chloride in an alkaline condition to prepare an intermediate IX, and further carrying out dehydrogenation reaction on the intermediate IX in the presence of an oxidizing agent to prepare an intermediate 9; carrying out a reaction on the intermediate VI and benzoyl chloride in the alkaline reaction to prepare the intermediate 9; and further carrying out dehydrogenation reaction on the intermediate III in the presence of an oxidizing agent to prepare the intermediate 11.

The invention relates to preparation and application of DNA vaccine that can resist to the infection of hepatitis C virus. The invention constructed a recombinant DNA vaccine that can express HCV enveloped glycoprotein E1 with molecular cloning techniques, on this basis constructed six N-glycosylation mutants M1-M6 of the E1 and select N-glycosylation mutant M2 as DNA vaccine that resist to infection of hepatitis C virus and application in the preparation of DNA vaccine that prevent the HCV virus infection. The advantages of the invention are : experiments reveal that N-sugar chain of HCV E1 enveloped glycoprotein can limit the host's cellular immune responses, its glycosylation may shield the T and B cell epitope of virus, thereby enable the virus to evade immune recognition; with E1 glycosylate mutants M2 may be used as DNA vaccines that are HCV therapeutic and preventive and enhance the immunogenicity, besides preparation of mutants M2 E1 glycosylate is simple, convenient and effective, and has good application prospect.

The invention discloses an application of artemisinin and derivatives thereof in preparation of medicaments for treating hepatitis C viruses (HCV). The medicaments which almost do not have toxic concentration are used for anti-virus test; and by detecting the influence of the artemisinin and the derivatives thereof such as dicyanogen artemisinin, artemether and artesunate on HCV replication, the artemisinin and the derivatives thereof serving as small molecular compounds have remarkable viral activity resistance and are dose-dependent. The artemisinin and the derivatives thereof which have already been used for clinical antimalarials have low toxic or side effect on a human body. The artemisinin and the derivatives thereof which almost do not have toxicity can inhibit about 90 percent of HCV replication, and are efficient and low-toxic anti-HCV compounds. The compounds have a broad prospect for developing anti-HCV medicaments.

The invention provides an anti-hepatitis C virus compound, a preparation method and an application thereof. The compound is the compound shown in a formula I or a stereisomer, a geometric isomer and a tautomer of the compound shown in the formula I, wherein R1 and R2 are respectively and independently selected from hydrogen, formyl group, benzoyl group and C1-C3 straight chain or branched chain alkyl group, and R1 and R2 can not be hydrogen at the same time. The compound has good lipid solubility and physical and chemical property, and bioavailability and effect in-vivo can be obviously increased.

The invention discloses a 2'-deoxy-2'-fluoro-2'-methylnucleoside derivative as well as a preparation method and application of the derivative in pharmaceuticals. The compound represented by the formula I has a better inhibiting effect on wild-type and S282T mutant-type HCV and low cytotoxicity and can be used in preparation of anti-hepatitis C virus drugs. The invention also provides a preparation method of the compound represented by the formula I.

An object of the present invention is to provide an antibody inhibiting infection with hepatitis C virus (HCV). The present invention provides an anti-hepatitis C virus antibody that recognizes a whole or a part of the conformation of a hepatitis C virus particle as an epitope and binds thereto, so as to be able to inhibit the binding of hepatitis C virus to the surface of a host cell and to inhibit HCV infection, a humanized antibody thereof, and an inhibitory agent for infection with hepatitis C virus.

The invention belongs to the field of the synthesis of anti-hepatitis C virus medicines by using medical intermediates, and particularly relates to an asymmetric synthesis method of a medical intermediate 2-azabicyclo [3. 1. 0] hexane-2, 3-tert-butyl dicarbonate. The asymmetric synthesis method is mainly characterized in that (2R) or (2S)-1, 2-tert-butyl dicarbonate-2, 3-pyrrole alkene is used as a raw material, methylbenzene, benzene or trihalomethylbenzene is used as a solvent, diiodomethane, chlorobromomethane, dibromomethane or diethylzinc is used as a cyclopropanation reagent, and after reaction, the compound 2-azabicyclo [3. 1. 0] hexane-2, 3-tert-butyl dicarbonate is obtained. The asymmetric synthesis method has the advantages that synthesis steps are simple, the yield is high, the cost is low, the cyclopropanation reagent is wide in selectivity, the synthesis process is simple, convenient and practical, and the like.

The invention relates to a method for selecting anti-hepatitis C medicine, which injects the artifical hepatitis C virus into tree mouse with negative hepatitis C, to build the hepatitis C natural infection model; via following steps as (1) composing hepatitis C virus; (2) injecting it into normal tree mouse, while the virus carried amount of each animal is higher than 105c; (3) fixing the hepatitis C virus naturally to infect the tree mouse model; (40 using the mouse model with positive hepatitis C virus to select the anti- hepatitis C medicine.

The present invention provides a kit for the detection of anti-hepatitis C virus (HCV) antibodies using a double-antigen sandwich technique, said kit carries out the detection by the process ‘solid support-first antigen-HCV antibody to be detected-second antigen-enzyme linked substance-recognizable signal’, wherein one or more coupling reactions between the second antigen and the enzyme linked substance occur, and the diluent for the second antigen and that for the enzyme linked substance are respectively placed into two container, they are added in order in two steps to reaction system and incubated respectively. The present invention can solve the following problems encountered by prior art: 1) the influence of the enzyme linked substance on the activity of the second antigen; 2) the mismatch of disulfide bonds in second antigen, thereby enhance the activity of the second antigen and obviate loss of enzyme activity, therefore, the present kit highly improves the sensitivity and specificity of the detection.

The invention relates to new application of a hydroquinone compound, particularly application of a hydroquinone compound (shikonin) in preparing medicines for resisting hepatitis C virus (HCV). The hydroquinone compound (shikonin) has obvious activity for resisting HCV, and the selection index is up to 43.56; and thus, the hydroquinone compound (shikonin) can be used as a lead compound for treating hepatitis C. The molecular formula of the hydroquinone compound (shikonin) is C16H16O5, and the chemical structural formula is disclosed in the specification.

The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

The present invention discloses a compound and applications of the compound in preparation of anti-hepatitis C virus drugs, wherein the structure formula of the compound is represented by a formula I or II, and the compound represented by the formula I or compound represented by the formula II can be subjected to drug combination with other anti-virus drugs such as interferon (PEG IFN-[alpha]), ribavirin (RBV), boceprevir, telaprevir, simeprevir, sofosbuvir, daclatasvir and the like t prepare anti-HCV products and other anti-virus infection products. According to the present invention, the compound has rich functional group diversity and modificability, and the product is relatively easy to separate and purify; the compounds can well inhibit HCV and other viruses, are obtained through phenotype screening, have different antiviral mechanisms, have extremely novel and innovated structures in the anti-virus field, and are not reported in the prior art; and the compound of the present invention has broad development and application prospect.

The invention discloses a hepatitis c virus adsorbent as well as a preparation method and an application thereof, and belongs to the field of medical and biological materials. The hepatitis c virus adsorbent comprises a carrier and a single strand desoxyribonucleic acid ligand combined with a hepatitis c virus envelope protein and connected to the carrier. The sequence of the ligand is as shown in SEQINNO.2. The hepatitis c virus adsorbent is obtained by obtaining a sensitive carrier surface through a chemical activating reaction and performing covalent linkage of the carrier surface with the artificially synthesized single strand desoxyribonucleic acid. The adsorbent is simple and convenient in synthetic method, short in process line and safe to prepare. The covalent bond is firm to connect and the ligand is stable to combine. The product has the characteristics of strong specificity, high absorption efficiency to hepatitis c virus particles, good regenerability and no toxicity and heat source reaction, and can be used for absorptive treatment of clinically and specifically eliminating hepatitis c virus particles in plasma and can be used for preparing anti-hepatitis c virus medicines.

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

The invention provides an application of a diterpenoid compound in treating hepatitis c virus (HCV) and belongs to the technical field of medicine. The invention discloses the diterpenoid compound with anti-hepatitis c virus (HCV) activity which is extracted and prepared from Phyllanthus reticulatus of Zhuang-medicine Hong Yuyan with Guang xi characteristics. The diterpenoid compound is characterized in that no cytotoxicity exists in a concentration range from 0-3125Mug / rnl, obvious inhibitory effects (p<0.05-p<0.01) over the HCV replicon ribonucleic acid (RNA) exist in a concentration range from 125 mu g / rnl-15625Mug / rnl. The diterpenoid compound (II) has a wide market future in the new medicine development of anti- hepatitis c virus (HCV).

The invention discloses a traditional Chinese medicine composition with high anti-hepatitis c virus activity. The traditional Chinese medicine composition is prepared from the following medicines in parts by weight: 4-15 parts of gardenia, 6-18 parts of rheum officinale and 6-18 parts of cortex phellodendri. The pharmacodynamics study proves that the traditional Chinese medicine composition disclosed by the invention is capable of relatively well inhibiting expression of HepG2 cell line HBeAg and HBsAg antigen, which are stably transfected by HBV genome, plays a certain anti-HBV activity role, is capable of obviously inhibiting expression of Rluc in an HCV-infected (JFH1-luc) report virus Huh7.5.1 cell culture solution and reducing the HCV-RNA content, shows good anti-HCV activity, and is especially significant on inhibition action of hepatitis c virus activity.